CRISPR Therapeutics (CRSP) PT Lowered to $55 at Stifel on Lower CAR-T Estimates
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $55.00 (from $57.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
